tetano
Editor, Senior Moderator
Emerg Infect Dis
. 2020 Nov 30;27(1).
doi: 10.3201/eid2701.203074. Online ahead of print.
IgG Seroconversion and Pathophysiology in Severe Acute Respiratory Syndrome Coronavirus 2 Infection
Henry M Staines, Daniela E Kirwan, David J Clark, Emily R Adams, Yolanda Augustin, Rachel L Byrne, Michael Cocozza, Ana I Cubas-Atienzar, Luis E Cuevas, Martina Cusinato, Benedict M O Davies, Mark Davis, Paul Davis, Annelyse Duvoix, Nicholas M Eckersley, Daniel Forton, Alice J Fraser, Gala Garrod, Linda Hadcocks, Qinxue Hu, Michael Johnson, Grant A Kay, Kesja Klekotko, Zawditu Lewis, Derek C Macallan, Josephine Mensah-Kane, Stefanie Menzies, Irene Monahan, Catherine M Moore, Gerhard Nebe-von-Caron, Sophie I Owen, Chris Sainter, Amadou A Sall, James Schouten, Christopher T Williams, John Wilkins, Kevin Woolston, Joseph R A Fitchett, Sanjeev Krishna, Tim Planche
Abstract
We investigated the dynamics of seroconversion in severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection. During March 29-May 22, 2020, we collected serum samples and associated clinical data from 177 persons in London, UK, who had SARS-CoV-2 infection. We measured IgG against SARS-CoV-2 and compared antibody levels with patient outcomes, demographic information, and laboratory characteristics. We found that 2.0%-8.5% of persons did not seroconvert 3-6 weeks after infection. Persons who seroconverted were older, were more likely to have concurrent conditions, and had higher levels of inflammatory markers. Non-White persons had higher antibody concentrations than those who identified as White; these concentrations did not decline during follow-up. Serologic assay results correlated with disease outcome, race, and other risk factors for severe SARS-CoV-2 infection. Serologic assays can be used in surveillance to clarify the duration and protective nature of humoral responses to SARS-CoV-2 infection.
Keywords: 2019 novel coronavirus disease; COVID-19; SARS-CoV-2; United Kingdom; antibodies; antibody responses; coronavirus; coronavirus disease; diagnostics; immunology; respiratory infections; serology; severe acute respiratory syndrome coronavirus 2; viruses; zoonoses.
. 2020 Nov 30;27(1).
doi: 10.3201/eid2701.203074. Online ahead of print.
IgG Seroconversion and Pathophysiology in Severe Acute Respiratory Syndrome Coronavirus 2 Infection
Henry M Staines, Daniela E Kirwan, David J Clark, Emily R Adams, Yolanda Augustin, Rachel L Byrne, Michael Cocozza, Ana I Cubas-Atienzar, Luis E Cuevas, Martina Cusinato, Benedict M O Davies, Mark Davis, Paul Davis, Annelyse Duvoix, Nicholas M Eckersley, Daniel Forton, Alice J Fraser, Gala Garrod, Linda Hadcocks, Qinxue Hu, Michael Johnson, Grant A Kay, Kesja Klekotko, Zawditu Lewis, Derek C Macallan, Josephine Mensah-Kane, Stefanie Menzies, Irene Monahan, Catherine M Moore, Gerhard Nebe-von-Caron, Sophie I Owen, Chris Sainter, Amadou A Sall, James Schouten, Christopher T Williams, John Wilkins, Kevin Woolston, Joseph R A Fitchett, Sanjeev Krishna, Tim Planche
- PMID: 33256890
- DOI: 10.3201/eid2701.203074
Abstract
We investigated the dynamics of seroconversion in severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection. During March 29-May 22, 2020, we collected serum samples and associated clinical data from 177 persons in London, UK, who had SARS-CoV-2 infection. We measured IgG against SARS-CoV-2 and compared antibody levels with patient outcomes, demographic information, and laboratory characteristics. We found that 2.0%-8.5% of persons did not seroconvert 3-6 weeks after infection. Persons who seroconverted were older, were more likely to have concurrent conditions, and had higher levels of inflammatory markers. Non-White persons had higher antibody concentrations than those who identified as White; these concentrations did not decline during follow-up. Serologic assay results correlated with disease outcome, race, and other risk factors for severe SARS-CoV-2 infection. Serologic assays can be used in surveillance to clarify the duration and protective nature of humoral responses to SARS-CoV-2 infection.
Keywords: 2019 novel coronavirus disease; COVID-19; SARS-CoV-2; United Kingdom; antibodies; antibody responses; coronavirus; coronavirus disease; diagnostics; immunology; respiratory infections; serology; severe acute respiratory syndrome coronavirus 2; viruses; zoonoses.